| 1 |
34243078 | Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. | 2021 Sep |
1 |
| 2 |
34733624 | Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer. | 2021 Sep |
4 |
| 3 |
27769870 | BRAF exon 15 mutations in pediatric renal stromal tumors: prevalence in metanephric stromal tumors. | 2017 Feb |
1 |
| 4 |
28648698 | Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. | 2017 Sep |
2 |
| 5 |
23879247 | Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. | 2014 Mar |
1 |
| 6 |
18056475 | 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. | 2007 Dec 1 |
1 |